LSD-Based Anxiety Treatment: What Did DT120 Trials Find?

What did the latest DT120 anxiety trial show?

Panorama tested an orally disintegrating formulation of lysergide, commonly known as LSD, in adults with generalized anxiety disorder. After one supervised administration, the 100-microgram group had an adjusted average anxiety-score reduction of 9.8 points, compared with 4.7 points for placebo. Lower scores indicate fewer symptoms. These are company-reported topline results, meaning a summary of principal findings rather than a complete journal publication. [Panorama results](https://ir.definiumtx.com/news-events/press-releases/detail/251/definium-therapeutics-announces-positive-topline-results-from-phase-3-panorama-study-of-dt120-odt-in-generalized-anxiety-disorder).

A separate phase 3 study, Voyage, provides supporting evidence. In August, Definium reported a 5.4-point advantage over placebo at the same assessment point among 214 participants. However, only 14% of treated participants met that trial's remission threshold, compared with 4% receiving placebo. Improvement therefore should not be interpreted as universal recovery. Neither comparison establishes superiority over an established anxiety medication or psychotherapy. [Voyage results](https://ir.definiumtx.com/news-events/press-releases/detail/243/definium-therapeutics-announces-positive-topline-results-from-phase-3-voyage-study-of-dt120-odt-in-generalized-anxiety-disorder).

What does published research show about benefits and side effects?

The development program includes a peer-reviewed phase 2b trial published in JAMA in 2025 under the earlier drug designation MM120. Researchers randomized 198 adults with moderate to severe generalized anxiety disorder to placebo or one of four doses. The primary dose-response analysis found statistically significant benefits at four weeks for the 100- and 200-microgram groups; the two lower-dose groups did not show significant advantages over placebo. This finding supports further investigation but does not establish that every patient benefits. [Published randomized trial](https://pubmed.ncbi.nlm.nih.gov/40906494/).

Visual perceptual changes, nausea and headache were among the common adverse events. At 100 micrograms, visual perceptual changes occurred in 92.5% of participants, compared with 10.3% receiving placebo. Those noticeable effects also complicate interpretation: participants may recognize which treatment they received. The trial used independent central symptom raters, but separating pharmacological benefit from expectations remains a challenge in psychedelic research. [JAMA trial findings](https://pubmed.ncbi.nlm.nih.gov/40906494/).

What questions remain before this could become routine treatment?

The FDA's July 2026 guidance identifies functional unblinding as a central problem: a psychedelic experience can reveal treatment assignment and influence symptom reporting or assessment. The agency recommends approaches such as independent blinded raters and careful consideration of comparison treatments. For DT120, this means the full evidence package matters more than a positive headline or a single statistical result. The strength and consistency of outcomes must be assessed alongside these potential sources of bias. [FDA clinical investigation guidance](https://www.fda.gov/media/169694/download?attachment=).

Delivery also requires substantial clinical support. King's College London describes Panorama administration in a dedicated hospital facility with doctors, nurses and other research staff; participants are not given psychedelics to take home. Its study description includes extended follow-up to examine durability and safety. These arrangements highlight unresolved practical questions about staffing, repeat treatment and access if approval eventually follows. A supervised research session cannot be assumed to have the same benefits or risks as unsupervised LSD use. [King's College London study information](https://www.kcl.ac.uk/research/panorama-study-mm120-lsd-for-generalised-anxiety-disorder).